CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
David Gallo, Jordan T.F. Young, Jimmy Fourtounis, Giovanni Martino, Alejandro Álvarez-Quilón, Cynthia Bernier, Nicole M. Duffy, Robert Papp, Anne Roulston, Rino Stocco, Janek Szychowski, Artur Veloso, Hunain Alam, Prasamit S. Baruah, Alexanne Bonneau Fortin, Julian Bowlan, Natasha Chaudhary, Jessica Desjardins, Evelyne Dietrich, Sara Fournier, Chloe Fugère-Desjardins, Théo Goullet de Rugy, Marie-Ève Leclaire, Bingcan Liu, Vivek Bhaskaran, Yaël Mamane, Henrique Melo, Olivier Nicolas, Akul Singhania, Rachel K. Szilard, Jan Tkáč, Shou Yun Yin, Stephen J. Morris, Michael Zinda, Cooper Marshall, Daniel Durocher
Abstract
Abstract Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour types, particularly in high-grade serous ovarian cancer, uterine tumours and gastro-oesophageal cancers, where high cyclin E levels are associated with genome instability, whole-genome doubling and resistance to cytotoxic and targeted therapies 1–4 . To uncover therapeutic targets for tumours with CCNE1 amplification, we undertook genome-scale CRISPR–Cas9-based synthetic lethality screens in cellular models of CCNE1 amplification. Here we report that increasing CCNE1 dosage engenders a vulnerability to the inhibition of the PKMYT1 kinase, a negative regulator of CDK1. To inhibit PKMYT1, we developed RP-6306, an orally bioavailable and selective inhibitor that shows single-agent activity and durable tumour regressions when combined with gemcitabine in models of CCNE1 amplification. RP-6306 treatment causes unscheduled activation of CDK1 selectively in CCNE1- overexpressing cells, promoting early mitosis in cells undergoing DNA synthesis. CCNE1 overexpression disrupts CDK1 homeostasis at least in part through an early activation of the MMB–FOXM1 mitotic transcriptional program. We conclude that PKMYT1 inhibition is a promising therapeutic strategy for CCNE1 -amplified cancers.